Posted by Michael Wonder on 16 May 2025
Kaerus Bioscience's lead candidate KER-0193 granted orphan drug designation and rare paediatric drug designation by US FDA for treatment of Fragile X syndrome
14 May 2025 - Kaerus Bioscience today announces that its lead candidate KER-0193 has been granted both orphan drug designation and rare paediatric drug designations for the treatment of Fragile X syndrome by the US FDA.
Discovered by Kaerus, KER-0193 is a novel, orally-bioavailable small molecule designed to specifically address hyper-excitability of brain function commonly associated with Fragile X syndrome.
